458 FINAL RESULTS OF THE PHARMACOKINETICS, EFFICACY, AND SAFETY/TOLERABILITY OF 400 AND 600 MG ONCE-DAILY DOSING OF ACH-1625 (HCV NS3 PROTEASE INHIBITOR) IN HCV GENOTYPE 1
2011
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
6
Citations
NaN
KQI